Streetbeat News

Earnings

FDMT

4D Molecular Therapeutics (4DMT) reported a narrower FY23 EPS loss of $(2.58) compared to $(3.32) YoY, and positive interim data from its Phase 2 PRISM study on 4D-150 for wet AMD, indicating progression to Phase 3 in Q1 2025. Positive data were also reported for 4D-710 in cystic fibrosis and 4D-310 in Fabry disease. Strategic partnerships with Astellas Pharma and Arbor Biotechnologies were highlighted. An upsized public offering raised $300 million, extending operational runway into H1 2027. The company anticipates key milestones across its portfolio in 2024.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:35 pm

NVTS

Navitas Semiconductor projects its Q1 2024 revenue to be around $23 million, plus or minus $500,000, which is below the estimated $24.693 million.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:34 pm

ZYXI

Zynex forecasts Q1 EPS of $0.03+, below the estimate of $0.04, and revenue of $47.5M+, slightly below the $47.74M estimate. For FY24, it expects EPS of $0.50+, under the $0.54 estimate, with net revenue of $227M+, below the $232.85M estimate.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:34 pm

KWR

Quaker Houghton anticipates that the current market conditions will continue until the first half of 2024. This outlook may influence the company's performance and strategic decisions moving forward.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:34 pm

ETNB

89bio (NASDAQ:ETNB) reported Q4 losses of $(0.50) per share, missing the consensus estimate of $(0.49) by 2.04%. This represents a 4.17% increase in losses compared to the same period last year.

Portfolio Pulse from Happy Mohamed

February 29, 2024 | 9:33 pm

TTEC

TTEC Holdings has provided its financial outlook for FY24, projecting adjusted EPS in the range of $1.15 to $1.86, which is below the estimated $2.21. The company also forecasts revenue to be between $2.275 billion and $2.365 billion, which falls short of the expected $2.452 billion.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:33 pm

SOUN

SoundHound AI Inc (NASDAQ:SOUN) reported Q4 earnings with an 80% year-over-year revenue increase to $17.147 million, missing estimates. The company had a loss of 7 cents per share, also below expectations. It highlighted a backlog growth to $661 million and a cash balance over $200 million. SoundHound anticipates 2024 revenue between $63 million and $77 million, with 2025 revenue expected to exceed $100 million. Shares dropped 11.6% after hours following the announcement.

Portfolio Pulse from Adam Eckert

February 29, 2024 | 9:33 pm

TTEC

TTEC Holdings has provided guidance for Q1 2024, projecting adjusted EPS to be between $0.25 and $0.34, which is below the estimated $0.41. Revenue is expected to be between $559M and $569M, also falling short of the estimated $593.940M.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:32 pm

SYRE

Spyre Therapeutics (NASDAQ:SYRE) reported a Q4 EPS loss of $(4.05), which is an improvement from the $(5.00) per share loss reported in the same quarter last year, marking a 19 percent increase in performance.

Portfolio Pulse from Happy Mohamed

February 29, 2024 | 9:32 pm

KWR

Quaker Houghton (NYSE:KWR) reported Q4 adjusted EPS of $1.78, surpassing the $1.67 estimate, marking a 28.06% year-over-year increase. However, its sales of $467.11M fell short of the $470.56M estimate, a 3.65% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:31 pm